Silo Pharma, Inc. (Nasdaq: SILO) has made an important stride in the field of medical research by entering into a research and development agreement to explore the potential of a dosage and time-release ketamine implant for the treatment of fibromyalgia. 

Fibromyalgia is a chronic condition that affects millions of American adults, causing widespread musculoskeletal pain along with accompanying symptoms such as memory issues, sleep problems, and fatigue. This debilitating condition impacts approximately 2% of the adult population in the United States. 

The research project aims to study the drug release and stability of the implant through analytical testing services and small batch pre-clinical proof of concept extrusion trials.

In response to this announcement, $SILO has shown a notable increase in pre-market of of $0.53 or 22.18%, reaching $2.92.

Meanwhile, in the entertainment industry, Netflix, Inc. (Nasdaq: NFLX) has received upward adjustments to its price target by two prominent financial firms. BofA Securities has raised the price target from $410 to $490, while Guggenheim has increased it from $375 to $500. 

Currently, $NFLX is trading at $430.21 in pre-market, showing an increase of $6.24 or 1.47%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)